Improved noninvasive diagnostic testing for malignant hyperthermia susceptibility from a combination of metabolites determined in vivo with 31P-magnetic resonance spectroscopy

J. F. Payen; J. L. Bosson; L. Bourdon; C. Jacquot; J. F. Le Bas; P. Stieglitz; A. L. Benabid

doi:10.1097/00000542-199305000-00007

Improved noninvasive diagnostic testing for malignant hyperthermia susceptibility from a combination of metabolites determined in vivo with ³¹P-magnetic resonance spectroscopy

J. F. Payen, J. L. Bosson, L. Bourdon, C. Jacquot, J. F. Le Bas, P. Stieglitz, A. L. Benabid

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

Background: Phosphorus magnetic resonance spectroscopy (³¹P-MRS) in vivo has been suggested recently as a possible noninvasive diagnostic test in malignant hyperthermia (MH) susceptibility. However, differences between protocols and also within subjects may have led to inconsistent MRS abnormalities reported during and after exercise. The aim of the current study was to detect discriminant abnormalities in the leg muscles using in vivo ³¹P-MRS during the rest period. Methods: Fourteen patients shown to be MH-susceptible and 22 patients MH-negative on the basis of in vitro caffeine/halothane contracture tests according to the European MH group protocol were compared to 36 control subjects using in vivo ³¹P-MRS during the rest period. A score of MRS combined abnormalities was calculated from a stepwise discriminant function analysis. Results: The MH-susceptible group had a significantly (P < 0.01) higher inorganic phosphate (Pi) to phosphocreatine (PCr) (Pi/PCr) value (0.134 ± 0.022) than either the MH- negative (0.097 ± 0.016) or the control (0.101 ± 0.017) group. The MH- susceptible group also exhibited a significantly (P < 0.01) higher phosphodiesters (PDE) to PCr (PDE/PCr) value (0.093 ± 0.056) than either the MH-negative (0.034 ± 0.021) or the control (0.029 ± 0.019) group. Combining both MRS parameters, 13 of the 14 MH-susceptible patients demonstrated abnormal MRS test results (score value < 1.65). Conversely, 21 of the 22 MH- negative patients had normal MRS results (score value ≥ 1.65). The sensitivity and specificity of this threshold value were 93 and 95%, respectively. Conclusions: This study confirms that ³¹P-MRS could be useful for distinguishing noninvasively between MH-susceptible and MH-negative patients if several MRS parameter are combined. Moreover, the present MRS approach appears to be more reliable and easier than that used during exercise.

Original language	English (US)
Pages (from-to)	848-855
Number of pages	8
Journal	Anesthesiology
Volume	78
Issue number	5
DOIs	https://doi.org/10.1097/00000542-199305000-00007
State	Published - 1993
Externally published	Yes

Keywords

Malignant hyperthermia: diagnosis of susceptibility; muscular metabolism
Measurement technique: phosphorus magnetic resonance; spectroscopy

ASJC Scopus subject areas

Anesthesiology and Pain Medicine

Access to Document

10.1097/00000542-199305000-00007

Cite this

@article{8b099d35663d4b78acb13b66608f0894,

title = "Improved noninvasive diagnostic testing for malignant hyperthermia susceptibility from a combination of metabolites determined in vivo with 31P-magnetic resonance spectroscopy",

abstract = "Background: Phosphorus magnetic resonance spectroscopy (31P-MRS) in vivo has been suggested recently as a possible noninvasive diagnostic test in malignant hyperthermia (MH) susceptibility. However, differences between protocols and also within subjects may have led to inconsistent MRS abnormalities reported during and after exercise. The aim of the current study was to detect discriminant abnormalities in the leg muscles using in vivo 31P-MRS during the rest period. Methods: Fourteen patients shown to be MH-susceptible and 22 patients MH-negative on the basis of in vitro caffeine/halothane contracture tests according to the European MH group protocol were compared to 36 control subjects using in vivo 31P-MRS during the rest period. A score of MRS combined abnormalities was calculated from a stepwise discriminant function analysis. Results: The MH-susceptible group had a significantly (P < 0.01) higher inorganic phosphate (Pi) to phosphocreatine (PCr) (Pi/PCr) value (0.134 ± 0.022) than either the MH- negative (0.097 ± 0.016) or the control (0.101 ± 0.017) group. The MH- susceptible group also exhibited a significantly (P < 0.01) higher phosphodiesters (PDE) to PCr (PDE/PCr) value (0.093 ± 0.056) than either the MH-negative (0.034 ± 0.021) or the control (0.029 ± 0.019) group. Combining both MRS parameters, 13 of the 14 MH-susceptible patients demonstrated abnormal MRS test results (score value < 1.65). Conversely, 21 of the 22 MH- negative patients had normal MRS results (score value ≥ 1.65). The sensitivity and specificity of this threshold value were 93 and 95%, respectively. Conclusions: This study confirms that 31P-MRS could be useful for distinguishing noninvasively between MH-susceptible and MH-negative patients if several MRS parameter are combined. Moreover, the present MRS approach appears to be more reliable and easier than that used during exercise.",

keywords = "Malignant hyperthermia: diagnosis of susceptibility; muscular metabolism, Measurement technique: phosphorus magnetic resonance; spectroscopy",

author = "Payen, {J. F.} and Bosson, {J. L.} and L. Bourdon and C. Jacquot and {Le Bas}, {J. F.} and P. Stieglitz and Benabid, {A. L.}",

year = "1993",

doi = "10.1097/00000542-199305000-00007",

language = "English (US)",

volume = "78",

pages = "848--855",

journal = "Anesthesiology",

issn = "0003-3022",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Improved noninvasive diagnostic testing for malignant hyperthermia susceptibility from a combination of metabolites determined in vivo with 31P-magnetic resonance spectroscopy

AU - Payen, J. F.

AU - Bosson, J. L.

AU - Bourdon, L.

AU - Jacquot, C.

AU - Le Bas, J. F.

AU - Stieglitz, P.

AU - Benabid, A. L.

PY - 1993

Y1 - 1993

N2 - Background: Phosphorus magnetic resonance spectroscopy (31P-MRS) in vivo has been suggested recently as a possible noninvasive diagnostic test in malignant hyperthermia (MH) susceptibility. However, differences between protocols and also within subjects may have led to inconsistent MRS abnormalities reported during and after exercise. The aim of the current study was to detect discriminant abnormalities in the leg muscles using in vivo 31P-MRS during the rest period. Methods: Fourteen patients shown to be MH-susceptible and 22 patients MH-negative on the basis of in vitro caffeine/halothane contracture tests according to the European MH group protocol were compared to 36 control subjects using in vivo 31P-MRS during the rest period. A score of MRS combined abnormalities was calculated from a stepwise discriminant function analysis. Results: The MH-susceptible group had a significantly (P < 0.01) higher inorganic phosphate (Pi) to phosphocreatine (PCr) (Pi/PCr) value (0.134 ± 0.022) than either the MH- negative (0.097 ± 0.016) or the control (0.101 ± 0.017) group. The MH- susceptible group also exhibited a significantly (P < 0.01) higher phosphodiesters (PDE) to PCr (PDE/PCr) value (0.093 ± 0.056) than either the MH-negative (0.034 ± 0.021) or the control (0.029 ± 0.019) group. Combining both MRS parameters, 13 of the 14 MH-susceptible patients demonstrated abnormal MRS test results (score value < 1.65). Conversely, 21 of the 22 MH- negative patients had normal MRS results (score value ≥ 1.65). The sensitivity and specificity of this threshold value were 93 and 95%, respectively. Conclusions: This study confirms that 31P-MRS could be useful for distinguishing noninvasively between MH-susceptible and MH-negative patients if several MRS parameter are combined. Moreover, the present MRS approach appears to be more reliable and easier than that used during exercise.

AB - Background: Phosphorus magnetic resonance spectroscopy (31P-MRS) in vivo has been suggested recently as a possible noninvasive diagnostic test in malignant hyperthermia (MH) susceptibility. However, differences between protocols and also within subjects may have led to inconsistent MRS abnormalities reported during and after exercise. The aim of the current study was to detect discriminant abnormalities in the leg muscles using in vivo 31P-MRS during the rest period. Methods: Fourteen patients shown to be MH-susceptible and 22 patients MH-negative on the basis of in vitro caffeine/halothane contracture tests according to the European MH group protocol were compared to 36 control subjects using in vivo 31P-MRS during the rest period. A score of MRS combined abnormalities was calculated from a stepwise discriminant function analysis. Results: The MH-susceptible group had a significantly (P < 0.01) higher inorganic phosphate (Pi) to phosphocreatine (PCr) (Pi/PCr) value (0.134 ± 0.022) than either the MH- negative (0.097 ± 0.016) or the control (0.101 ± 0.017) group. The MH- susceptible group also exhibited a significantly (P < 0.01) higher phosphodiesters (PDE) to PCr (PDE/PCr) value (0.093 ± 0.056) than either the MH-negative (0.034 ± 0.021) or the control (0.029 ± 0.019) group. Combining both MRS parameters, 13 of the 14 MH-susceptible patients demonstrated abnormal MRS test results (score value < 1.65). Conversely, 21 of the 22 MH- negative patients had normal MRS results (score value ≥ 1.65). The sensitivity and specificity of this threshold value were 93 and 95%, respectively. Conclusions: This study confirms that 31P-MRS could be useful for distinguishing noninvasively between MH-susceptible and MH-negative patients if several MRS parameter are combined. Moreover, the present MRS approach appears to be more reliable and easier than that used during exercise.

KW - Malignant hyperthermia: diagnosis of susceptibility; muscular metabolism

KW - Measurement technique: phosphorus magnetic resonance; spectroscopy

UR - http://www.scopus.com/inward/record.url?scp=0027287925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027287925&partnerID=8YFLogxK

U2 - 10.1097/00000542-199305000-00007

DO - 10.1097/00000542-199305000-00007

M3 - Article

C2 - 8489056

AN - SCOPUS:0027287925

SN - 0003-3022

VL - 78

SP - 848

EP - 855

JO - Anesthesiology

JF - Anesthesiology

IS - 5

ER -